ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth
Berlin, Germany, January 7, 2025 ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an..
ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023
Berlin, Germany – March 30, 2023 ProBioGen, the Berlin-based CDMO and technology provider, reported today that revenues for the fiscal year 2022 (FY22) grew 35% vs FY21. In a year..
ProBioGen’s Growth Strategy Continues Successfully
Julian Collins, Jana Windt and Michiel Stork Join Biopharma Company’s Leadership Team Berlin, Germany – March 2, 2023 ProBioGen has seen significant growth with over 300 employees..
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Apr 12, 2023
